文献速递肝病消化道肿瘤与早癌

晚期肝病无未定性结节患者丙型肝炎治愈后肝癌风险

Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
PubMed 文献 · J Hepatol · 2021-11-29

前瞻性研究纳入185例直接抗病毒药物治疗后获持续病毒学应答的F3/F4期丙型肝炎患者,且应答后30天内超声排除肝细胞癌及未定性结节。全队列肝细胞癌发生率为1.46/100人年(95%CI 0.79-2.71),F4期仅2.24/100人年(95%CI 1.21-4.17),临床显著门脉高压者3.63/100人年(95%CI 1.95-6.74),F3期无肝细胞癌发生。

要点

  • F4期且无未定性结节者获持续病毒学应答后仍存在肝细胞癌风险。
  • F3期无未定性结节者未观察到肝细胞癌,但需前瞻性研究确认。
  • 临床显著门脉高压者肝细胞癌发生率更高。

核心结论

  • 获持续病毒学应答时无未定性结节的肝硬化患者仍有肝细胞癌发生风险。
  • F3期患者无肝细胞癌发生,但需前瞻性研究以将其排除出筛查程序。

研究设计与样本

  • 前瞻性研究纳入185例丙型肝炎病毒感染者,其中F3期63例、F4期122例,均无肝细胞癌史。
  • 患者均在获持续病毒学应答后30天内经超声排除肝细胞癌及未定性结节。
  • 每6个月评估一次,直至发生原发性肝癌、死亡或撤回知情同意。

主要发现

  • 全队列肝细胞癌发生率为1.46/100人年(95%CI 0.79-2.71)。
  • F4期患者肝细胞癌发生率为2.24/100人年(95%CI 1.21-4.17)。
  • 临床显著门脉高压患者肝细胞癌发生率为3.63/100人年(95%CI 1.95-6.74)。
  • F3期患者无肝细胞癌发生。
  • 从持续病毒学应答至肝细胞癌发生的中位时间为28.1个月,另发现12例非原发性肝癌。

关键数值与推荐

  • 肝硬化患者中92%为Child-Pugh A级,42.7%有临床显著门脉高压。
  • 白蛋白-胆红素评分为1分者占84.9%,为2分者占15.1%。
  • 中位临床随访52.4个月,中位影像学随访48个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需前瞻性研究以将F3期患者排除出筛查程序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recognition of non-characterized liver nodules (NCLN) prior to direct-acting antivirals (DAAs) is associated with increased hepatocellular carcinoma (HCC) risk in patients with HCV. The risk of HCC has not been defined in F3/F4 patients in whom NCLN have been ruled-out before starting DAAs and at sustained virological response (SVR). This study aimed to estimate HCC incidence in this population. METHODS: We performed a prospective study including HCV-infected patients with F3/F4 fibrosis, without a history of HCC, and who achieved SVR after DAAs. Patients were only included if they had undergone ultrasound imaging that excluded the presence of HCC/NCLN within 30 days after SVR. All patients were evaluated every 6 months until developing primary liver cancer, death or withdrawal of informed consent. HCC incidence was expressed per 100 patient-years (/100PY). Adherence to screening program was calculated every 6 months for the first 48 months. RESULTS: A total of 185 patients (63/122, F3/F4) were included. Among those with cirrhosis, 92% were Child-Pugh A and 42.7% had clinically significant portal hypertension (CSPH). Albumin-bilirubin score was 1 in 84.9% and 2 in 15.1% of patients, respectively. The median clinical and radiologic follow-up was 52.4 months and 48 months, respectively. Ten patients developed HCC: HCC incidence was 1.46/100PY (95% CI 0.79-2.71) in the whole cohort, 2.24/100PY (95% CI 1.21-4.17) in F4 only and 3.63/100PY (95% CI 1.95-6.74) in patients with CSPH. No HCC was registered in patients with F3. Median time between SVR and HCC occurrence was 28.1 months; 12 non-primary liver cancers were also identified. CONCLUSIONS: Patients with cirrhosis without NCLN at SVR remain at risk of HCC development. The absence of HCC in patients with F3 reinforces their marginal cancer risk, but prospective studies are needed to exclude them from screening programs. LAY SUMMARY: Patients with HCV-related cirrhosis, without non-characterized liver nodules at sustained virologic response, remain at risk of hepatocellular carcinoma despite viral cure. However, the cancer risk after successful direct-acting antiviral treatment is marginal in patients with F3 fibrosis without non-characterized liver nodules. If confirmed in larger prospective studies, current screening recommendations may need to be revisited in this group of patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Sanduzzi-Zamparelli M, Mariño Z, Lens S, et al. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. J Hepatol. 2021. PMID: 34856322. doi:10.1016/j.jhep.2021.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。